Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

LNTHBullishM&Anews

High materiality9/10

Curium to Acquire Lantheus for Up to $114.50/Share in Cash

Aug 3, 2026, 7:33 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Definitive cash offer with a meaningful premium to multiple VWAP benchmarks; likely compresses discount to offer price as arbitrage closes, barring deal termination risk.

AI summary

What happened, with direct paths to the underlying reporting

Curium will acquire Lantheus in a cash deal valued at up to $114.50 per share, including CVRs up to $12. The transaction values Lantheus at about $8.0B and would create a global radiopharmaceutical leader across diagnostics and therapeutics in 70+ countries. Closing is expected in the first half of 2027, pending approvals.

Curium to acquire Lantheus for up to $114.50 per LNTH share in cash.
Deal includes $102.50 cash at closing plus up to $12 CVRs through 2030.
Premiums: 38% to 60-day VWAP and 29% to 30-day VWAP; close targeted H1 2027.
Combined entity spans 70+ countries; value up to $8.0 billion; LNTH board unanimous.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Curium to Acquire Lantheus for Up to $114.50/Share in Cash

FDA approval for Lantheus brain imaging agent could boost Alzheimer's diagnostics

FDA CRL Delays LNTH-2501 NDA on Third-Party Manufacturing Issues

Lantheus Considers Sale After $7 Billion Offer from Curium Pharma

Lantheus Holdings Posts Strong Q1 Earnings, Signals Continued Growth Potential